Characterization of oligopeptides that cross-react with carbohydrate-specific antibodies by real time kinetics, in-solution competition enzyme-linked immunosorbent assay, and immunological analyses.

The Journal of Biological Chemistry
Paul J BrettBambos M Charalambous

Abstract

Phage displaying random cyclic 7-mer, and linear 7-mer and 12-mer peptides at the N terminus of the coat protein, pIII, were panned with the murine monoclonal antibody, 9-2-L379 specific for meningococcal lipo-oligosaccharide. Five cyclic peptides with two sequence motifs, six linear 7-mers, and five linear 12-mers with different sequence motifs were identified. Only phage displaying cyclic peptides were specifically captured by and were antigenic for 9-2-L379. Monoclonal antibody 9-2-L379 exhibited "apparent" binding affinities to the cyclic peptides between 11 and 184 nm, comparable with lipo-oligosaccharide. All cyclic peptides competed with the binding of 9-2-L379 to lipo-oligosaccharide with EC(50) values in the range 10-105 microm, which correlated with their apparent binding affinities. Structural modifications of the cyclic peptides eliminated their ability to bind and compete with monoclonal antibody 9-2-L379. Mice (C3H/HeN) immunized with the cyclic peptide with optimal apparent binding affinity and EC(50) of competition elicited cross-reactive antibodies to meningococcal lipo-oligosaccharide with end point dilution serum antibody titers of 3200. Cyclic peptides were converted to T-cell-dependent immunogens without di...Continue Reading

References

Jan 1, 1992·Microbial Pathogenesis·M A Westerink, P C Giardina
Jul 1, 1984·The Journal of Infectious Diseases·J M GriffissC J Baker
Apr 25, 1995·Proceedings of the National Academy of Sciences of the United States of America·M A WesterinkT Kieber-Emmons
Mar 1, 1993·Microbiological Reviews·A F VerheulJ T Poolman
Jan 1, 1996·Microbiology·J S Evans, M C J Maiden
Jan 1, 1996·Critical Reviews in Microbiology·A PrestonM A Apicella
Dec 1, 1996·Trends in Biochemical Sciences·P Schuck, A P Minton
Feb 1, 1997·Hybridoma·T Kieber-EmmonsZ Steplewski
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·S L HarrisJ K Scott
Jun 1, 1997·Nature Biotechnology·M AgadjanyanT Kieber-Emmons
Nov 22, 1997·European Journal of Immunology·A PhaliponF Felici
Feb 28, 1998·Immunologic Research·T Kieber-Emmons
Nov 11, 1999·Journal of Molecular Biology·X De BolleP Mertens
Aug 10, 2000·Nature Biotechnology·P De BerardinisJ Guardiola
Nov 9, 2001·Journal of Medical Microbiology·B M Charalambous, I M Feavers

❮ Previous
Next ❯

Citations

Jan 17, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Alfredo MenendezJamie K Scott
May 19, 2007·Shock·Bambos M CharalambousH E Montgomery
Jan 12, 2011·Expert Opinion on Biological Therapy·Mark AgostinoElizabeth Yuriev
Oct 29, 2005·Scandinavian Journal of Immunology·H TiwanaB M Charalambous
Aug 4, 2007·Molecular Immunology·Angela C CendronP Mark Hogarth
Jan 9, 2004·Expert Review of Vaccines·Clementien L Vermont, Germie P J M van den Dobbelsteen
Dec 4, 2003·FEBS Letters·Teruhiko MatsubaraKatsuhiro Kawashiro
Jan 21, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Miha VodnikMojca Lunder
Nov 28, 2012·Biomedizinische Technik. Biomedical Engineering·Elias EstephanBernard Levallois

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.